A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT Study

Peer Review reports

Original Submission
17 Oct 2011	Submitted	Original manuscript
20 Oct 2011	Author responded	Author comments - Elaine Rogers
Resubmission - Version 2
20 Oct 2011	Submitted	Manuscript version 2
7 Nov 2011	Author responded	Author comments - Elaine Rogers
Resubmission - Version 3
7 Nov 2011	Submitted	Manuscript version 3
Publishing
23 Nov 2011	Editorially accepted
23 Nov 2011	Article published	10.1186/1471-2407-11-493

Back to article page